CoChat

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Purpose Although improved long-term prognoses for patients with metastatic breast cancer (MBC) have been demonstrated, few reports address overall survival (OS) with sufficient follow-up. Furthermore, the relevance of immunohistological subtypes to OS in MBC has not been clarified. Methods We evaluated, retrospectively, the OS of patients who had been initiated on systemic therapy for MBC between 2000 and 2008. Results The subjects of this study were 527 patients with MBC treated by systemic therapy. The median survival time (MST) was 55.5 months. The MST for each immunohistological subtype was as follows: luminal, 59.9 months; luminal-HER2, not reached; triple-negative, 18.6 months; and HER2-enriched, 49.9 months. According to multivariate analysis, metastasis-free intervals of ≥2 years and treatment with anthracycline for MBC were predictive of better OS. The predictors of shorter OS included disease progression after first-line treatment for MBC, triple-negative, and all histological factors, except papillotubular carcinoma, with liver metastasis, and having three or more initial metastatic sites. Conclusions The prognosis of the patients with MBC in this series was better than that reported before 2000, which is probably attributable to the use of novel, improved pharmacological agents. For example, luminal-HER2 tumors can be treated using both aromatase inhibitors and trastuzumab. Because of the lower toxicities, it is now possible to administer these agents for longer p…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00595-015-1252-x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 33 references

Cited by

See all 45

Metadata

Authors
Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., & Hatake, K.
Affiliations
  • The Cancer Institute Hospital (JP)
  • Japanese Foundation For Cancer Research (JP)
  • Jichi Medical University (JP)
Corresponding author
Kobayashi, Kokoro
Venue
Surgery Today
Published
2015-10-14
Volume
46
Issue
7
Pages
821-826
ISSN
  • 0047-1909 (ISSN-L)
  • 0941-1291
  • 1436-2813
OpenAlex
W1898450115
Cited by
45
References
33
Citations by year
2025: 2 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 2 · 2016: 5
FWCI
1.65
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Surgery Today (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
metastatic breast cancer, overall survival, luminal breast cancer, triple-negative breast cancer, HER2-enriched breast cancer, anthracycline chemotherapy, metastasis-free interval, prognostic factors, papillotubular carcinoma, liver metastasis, trastuzumab, aromatase inhibitors
MeSH terms
Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Follow-Up Studies, Humans, Immunohistochemistry, Middle Aged, Prognosis, Retrospective Studies, Time Factors, Survival Rate, Erb-b2 Receptor Tyrosine Kinases, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1007/s00595-015-1252-x
The paper
Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., & Hatake, K. (2016). Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surgery Today. https://doi.org/10.1007/s00595-015-1252-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.